Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial

(2013) C. Denkert et al.   ANNALS OF ONCOLOGY

An International Ki67 Reproducibility Study

(2013) Mei-Yin C. Polley et al.   JNCI-Journal of the National Cancer Institute

When to order a biopsy to characterise a metastatic relapse in breast cancer

(2012) T. Foukakis et al.   ANNALS OF ONCOLOGY

Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer

(2012) Y. Delpech et al.   BREAST CANCER RESEARCH AND TREATMENT

Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression

(2012) Linda Sofie Lindström et al.   JOURNAL OF CLINICAL ONCOLOGY

Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer

(2011) H. Anderson et al.   ANNALS OF ONCOLOGY

Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review

(2011) Elisabeth Luporsi et al.   BREAST CANCER RESEARCH AND TREATMENT

Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden

(2011) Theodoros Foukakis et al.   BREAST CANCER RESEARCH AND TREATMENT

Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies

(2011) Eitan Amir et al.   CANCER TREATMENT REVIEWS

Immunocytochemistry: an indispensable technique in routine cytology

(2011) L. Skoog et al.   CYTOPATHOLOGY

Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer

(2011) Eitan Amir et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial

(2009) Judith Hugh et al.   JOURNAL OF CLINICAL ONCOLOGY

Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor–Positive Breast Cancer

(2009) Frédérique Penault-Llorca et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole

(2008) Giuseppe Viale et al.   JOURNAL OF CLINICAL ONCOLOGY